That development of one or the other tumor type is not exclusively linked to a specific mutation is supported by reports of RAS driver mutations in BRAFV600E-negative follicular-variant PTC (6, 7, 63) and BRAF mutations in rare cases of FTC (8, 9). This evidence concerns the gene BRAF and neoplasm.